248 related articles for article (PubMed ID: 22917553)
1. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
Neilan TG; Coelho-Filho OR; Pena-Herrera D; Shah RV; Jerosch-Herold M; Francis SA; Moslehi J; Kwong RY
Am J Cardiol; 2012 Dec; 110(11):1679-86. PubMed ID: 22917553
[TBL] [Abstract][Full Text] [Related]
2. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
Neilan TG; Coelho-Filho OR; Shah RV; Feng JH; Pena-Herrera D; Mandry D; Pierre-Mongeon F; Heydari B; Francis SA; Moslehi J; Kwong RY; Jerosch-Herold M
Am J Cardiol; 2013 Mar; 111(5):717-22. PubMed ID: 23228924
[TBL] [Abstract][Full Text] [Related]
3. Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors.
Chhikara S; Hooks M; Athwal PSS; Hughes A; Ismail MF; Joppa S; Velangi PS; Nijjar PS; Blaes AH; Shenoy C
Eur Heart J Cardiovasc Imaging; 2022 Aug; 23(9):1222-1230. PubMed ID: 34297807
[TBL] [Abstract][Full Text] [Related]
4. The Extent of Late Gadolinium Enhancement Can Predict Adverse Cardiac Outcomes in Patients with Non-Ischemic Cardiomyopathy with Reduced Left Ventricular Ejection Fraction: A Prospective Observational Study.
Kim EK; Lee GY; Jang SY; Chang SA; Kim SM; Park SJ; Choi JO; Park SW; Choe YH; Lee SC; Oh JK
Korean J Radiol; 2021 Mar; 22(3):324-333. PubMed ID: 32932562
[TBL] [Abstract][Full Text] [Related]
5. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.
Wu KC; Weiss RG; Thiemann DR; Kitagawa K; Schmidt A; Dalal D; Lai S; Bluemke DA; Gerstenblith G; Marbán E; Tomaselli GF; Lima JA
J Am Coll Cardiol; 2008 Jun; 51(25):2414-21. PubMed ID: 18565399
[TBL] [Abstract][Full Text] [Related]
6. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and prognostic significance of left ventricular myocardial late gadolinium enhancement in severe aortic stenosis.
Rajesh GN; Thottian JJ; Subramaniam G; Desabandhu V; Sajeev CG; Krishnan MN
Indian Heart J; 2017; 69(6):742-750. PubMed ID: 29174252
[TBL] [Abstract][Full Text] [Related]
9. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
[TBL] [Abstract][Full Text] [Related]
10. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy.
Harries I; Biglino G; Baritussio A; De Garate E; Dastidar A; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2019 Oct; 292():248-252. PubMed ID: 31006597
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular magnetic resonance parametric techniques to characterize myocardial effects of anthracycline therapy in adults with normal left ventricular ejection fraction: a systematic review and meta-analysis.
Musella F; Librera M; Sibilio G; Boccalatte M; Tagliamonte G; Cavaglià E; Ferrara I; Puglia M; Dell'Aversana S; Ducci CB; Dellegrottaglie S; Savarese G; Scatteia A
Curr Probl Cardiol; 2024 Jul; 49(7):102609. PubMed ID: 38697332
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis.
Flamée L; Symons R; Degtiarova G; Dresselaers T; Gheysens O; Wuyts W; Van Cleemput J; Bogaert J
Eur Radiol; 2020 Jul; 30(7):3702-3710. PubMed ID: 32166494
[TBL] [Abstract][Full Text] [Related]
13. Right Ventricular Ejection Fraction Is Incremental to Left Ventricular Ejection Fraction for the Prediction of Future Arrhythmic Events in Patients With Systolic Dysfunction.
Mikami Y; Jolly U; Heydari B; Peng M; Almehmadi F; Zahrani M; Bokhari M; Stirrat J; Lydell CP; Howarth AG; Yee R; White JA
Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28087564
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
15. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.
Greulich S; Deluigi CC; Gloekler S; Wahl A; Zürn C; Kramer U; Nothnagel D; Bültel H; Schumm J; Grün S; Ong P; Wagner A; Schneider S; Nassenstein K; Gawaz M; Sechtem U; Bruder O; Mahrholdt H
JACC Cardiovasc Imaging; 2013 Apr; 6(4):501-11. PubMed ID: 23498675
[TBL] [Abstract][Full Text] [Related]
16. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
Oberholzer K; Kunz RP; Dittrich M; Thelen M
Rofo; 2004 Sep; 176(9):1245-50. PubMed ID: 15346258
[TBL] [Abstract][Full Text] [Related]
17. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
20. Left Ventricular Entropy Is a Novel Predictor of Arrhythmic Events in Patients With Dilated Cardiomyopathy Receiving Defibrillators for Primary Prevention.
Muthalaly RG; Kwong RY; John RM; van der Geest RJ; Tao Q; Schaeffer B; Tanigawa S; Nakamura T; Kaneko K; Tedrow UB; Stevenson WG; Epstein LM; Kapur S; Zei PC; Koplan BA
JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1177-1184. PubMed ID: 30121262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
